{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:18:12Z","timestamp":1782739092054,"version":"3.54.5"},"reference-count":42,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Women and Gender Equality Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Purpose: To characterize the histologic and molecular subtype distribution of, and survival from, breast cancer (BC) among Canadian women overall, and by stage and age at diagnosis. Methods: Invasive BC cases from the Canadian Cancer Registry for women aged 15\u201399 years between 2012 and 2017 in Canada, excluding Quebec, were examined using pre-existing mortality linkages. Stage at diagnosis, molecular, and histologic subtypes, and 5-year net survival (NS) by age, subtype, and stage were determined. Results: 107,271 women with BC were included. Luminal A was the most common subtype, present in increasing proportions as women aged, up to a maximum of 55% of cases in 70\u201374. Ductal and luminal A were most likely to be diagnosed at stage I, while HER2+ had the highest proportion of diagnosis at stage III; triple negative (TN) and unknown had the highest proportion of stage IV. For all stages combined, luminal A had a five-year NS of 98%, while TN was 74%. NS for stage I BC was 99\u2013100% for all subtypes, excepting TN, which was 96%. Survival decreased with advancing stage, most markedly for TN, for which stage III was 47% and stage IV 7%. Survival by equivalent stage and subtype was comparable across age groups but declined in older age categories. Conclusions: The varying natural histories of BC subtypes and histologies can inform prognoses, health system economics, and screening practices. The NS of 96% or greater for stage I, regardless of subtype, highlights the importance of early detection for all subtypes of BC, especially in aggressive subtypes.<\/jats:p>","DOI":"10.3390\/curroncol31090411","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:23:04Z","timestamp":1726737784000},"page":"5544-5556","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Landscape of Breast Cancer Molecular and Histologic Subtypes in Canada"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5422-8428","authenticated-orcid":false,"given":"Anna N.","family":"Wilkinson","sequence":"first","affiliation":[{"name":"Department of Family Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-6780","authenticated-orcid":false,"given":"Larry F.","family":"Ellison","sequence":"additional","affiliation":[{"name":"Centre for Population Health Data at Statistics Canada, Government of Canada, Ottawa, ON K1A 0T6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon F.","family":"McGee","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Billette","sequence":"additional","affiliation":[{"name":"Centre for Population Health Data at Statistics Canada, Government of Canada, Ottawa, ON K1A 0T6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0367-2219","authenticated-orcid":false,"given":"Jean M.","family":"Seely","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cpet.2018.02.004","article-title":"Molecular classification of breast cancer","volume":"13","author":"Provenzano","year":"2018","journal-title":"PET Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","first-page":"2929","article-title":"Breast cancer intrinsic subtype classification, clinical use and future trends","volume":"5","author":"Dai","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2014Dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/bcr2904","article-title":"Luminal-B breast cancer and novel therapeutic targets","volume":"13","author":"Tran","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1200\/JCO.2012.46.1574","article-title":"Patterns of recurrence and outcome according to breast cancer subtypes in lymph node\u2013negative disease: Results from International Breast Cancer Study Group Trials VIII and IX","volume":"31","author":"Sun","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"New Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"vi23","DOI":"10.1093\/annonc\/mds191","article-title":"Imaging of triple-negative breast cancer","volume":"23","author":"Dogan","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.14366\/usg.16030","article-title":"Molecular subtypes and imaging phenotypes of breast cancer","volume":"35","author":"Cho","year":"2016","journal-title":"Ultrasonography"},{"key":"ref_12","first-page":"E734","article-title":"Breast cancer survival by molecular subtype: A population-based analysis of cancer registry data","volume":"5","author":"Fallahpour","year":"2017","journal-title":"Can. Med. Assoc. Open Access J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3390\/curroncol30090571","article-title":"Capturing the true cost of breast cancer treatment: Molecular subtype and stage-specific per-case activity-based costing","volume":"30","author":"Wilkinson","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_14","unstructured":"(2024, September 10). Statistics Canada: Canadian Cancer Registry 1992 to 2017. Available online: https:\/\/www23.statcan.gc.ca\/imdb\/p2SV.pl?Function=getSurvey&Id=1215604."},{"key":"ref_15","first-page":"3","article-title":"Five-year cancer survival by stage at diagnosis in Canada","volume":"34","author":"Ellison","year":"2023","journal-title":"Health Rep."},{"key":"ref_16","unstructured":"Fritz, A., Percy, C., Jack, A., Shanmugaratnam, K., Sobin, L., Parkin, D.M., and Whelan, S. (2013). International Classification of Diseases for Oncology, First Revision, World Health Organization. [3rd ed.]."},{"key":"ref_17","unstructured":"Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2021). SEER Cancer Statistics Review, 1975\u20132018."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E601","DOI":"10.1503\/cmaj.212097","article-title":"Projected estimates of cancer in Canada in 2022","volume":"194","author":"Brenner","year":"2022","journal-title":"Can. Med Assoc. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.canep.2010.06.015","article-title":"Measuring the effect of including multiple cancers in survival analyses using data from the Canadian Cancer Registry","volume":"34","author":"Ellison","year":"2010","journal-title":"Cancer Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/ijc.28990","article-title":"Cancer incidence, survival and mortality: Explaining the concepts","volume":"135","author":"Ellis","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_21","unstructured":"Edge, S., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., and Trotti, A. (2010). AJCC Cancer Staging Manual, Springer. [7th ed.]."},{"key":"ref_22","unstructured":"Dickman, P.W. (2024, September 10). Estimating and Modelling Relative Survival Using SAS. Available online: http:\/\/www.pauldickman.com\/software\/sas."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","article-title":"On estimation in relative survival","volume":"68","author":"Perme","year":"2012","journal-title":"Biometrics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.annepidem.2005.02.017","article-title":"An empirical evaluation of period survival analysis using data from the Canadian Cancer Registry","volume":"16","author":"Ellison","year":"2006","journal-title":"Ann. Epidemiol."},{"key":"ref_25","unstructured":"Statistics Canada (2020). Life Tables, Canada, Provinces and Territories, 1980\/1982 to 2016\/2018 (Catalogue No. 84-537-X)."},{"key":"ref_26","first-page":"14","article-title":"The cancer survival index: Measuring progress in cancer survival to help evaluate cancer control efforts in Canada","volume":"32","author":"Ellison","year":"2021","journal-title":"Health Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-015-0546-7","article-title":"Lobular breast cancer: Incidence and genetic and non-genetic risk factors","volume":"17","author":"Dossus","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yang, C., Lei, C., Zhang, Y., Zhang, J., Ji, F., Pan, W., Zhang, L., Gao, H., Yang, M., and Li, J. (2020). Comparison of overall survival between invasive lobular breast carcinoma and invasive ductal breast carcinoma: A propensity score matching study based on SEER database. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.590643"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3747\/co.27.5769","article-title":"A population-based analysis of breast cancer incidence and survival by subtype in Ontario women","volume":"27","author":"Seung","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6387378","DOI":"10.1155\/2020\/6387378","article-title":"Breast cancer in the United States: A cross-sectional overview","volume":"2020","author":"Bilani","year":"2020","journal-title":"J. Cancer Epidemiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2013226","DOI":"10.1001\/jamanetworkopen.2020.13226","article-title":"Incidence trends of breast cancer molecular subtypes by age and race\/ethnicity in the US from 2010 to 2016","volume":"3","author":"Acheampong","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast cancer survival by molecular subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E1441","DOI":"10.1503\/cmaj.180463","article-title":"Recommendations on screening for breast cancer in women aged 40\u201374 years who are not at increased risk for breast cancer","volume":"190","author":"Klarenbach","year":"2018","journal-title":"Can. Med Assoc. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"32S","DOI":"10.1177\/0272989X17743236","article-title":"Estimating breast cancer survival by molecular subtype in the absence of screening and adjuvant treatment","volume":"38","author":"Munoz","year":"2018","journal-title":"Med. Decis. Mak."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sturesdotter, L., Sandsveden, M., Johnson, K., Larsson, A.M., Zackrisson, S., and Sartor, H. (2020). Mammographic tumour appearance is related to clinicopathological factors and surrogate molecular breast cancer subtype. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-77053-7"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e230027","DOI":"10.1148\/rg.230027","article-title":"Imaging challenges in diagnosing triple-negative breast cancer","volume":"43","author":"Schopp","year":"2023","journal-title":"Radiographics"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wilson, N., Ironside, A., Diana, A., and Oikonomidou, O. (2021). Lobular breast cancer: A review. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.591399"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clinimag.2021.08.013","article-title":"Screening mammography mitigates breast cancer disparities through early detection of triple negative breast cancer","volume":"80","author":"Bayard","year":"2021","journal-title":"Clin. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2023.25881","article-title":"Analysis of Breast Cancer Mortality in the US\u20141975 to 2019","volume":"331","author":"Sun","year":"2024","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.surg.2016.03.031","article-title":"Breast cancer biology varies by method of detection and may contribute to overdiagnosis","volume":"160","author":"Hayse","year":"2016","journal-title":"Surgery"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/411\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:57:47Z","timestamp":1760111867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["curroncol31090411"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31090411","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]}}}